| Item 8.01. | Other Events. |
On June 30, 2008, Salix Pharmaceuticals, Ltd. issued a press release announcing the initiation of Phase 3 for rifaximin to assess its efficacy in the treatment of non-constipation irritable bowel syndrome. A copy of the press release is attached hereto as an exhibit.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. |
Description | |
| 99.1 | Press release dated June 30, 2008. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| SALIX PHARMACEUTICALS, LTD. | ||
| Date: July 1, 2008 | ||
| /s/ Adam C. Derbyshire | ||
| Adam C. Derbyshire | ||
| Senior Vice President and Chief Financial Officer | ||